Biologicals

Meningococcal

Recommendations to assure the quality, safety and efficacy of Group A Meningococcal Conjugate vaccines

ECBS 2006

Recommendations for the production and control of group C meningococcal conjugate vaccines, TRS 926, Annex 3

Recommendations for the production and control of Meningococcal group C conjugate vaccines, TRS 924, 2004, Annex 2

Requirements for Meningococcal Polysaccharide vaccine (Amendment 1999) TRS 904, 2002 Annex 2

Requirements for meningococcal polysaccharide vaccine, Addendum 1980, TRS 658 Annex 6

Requirements for Meningococcal Polysaccharide vaccine: Adopted 1975, TRS 594, Annex 2

UPCOMING EVENTS


  • WHO Informal Consultation on Regulatory considerations for evaluation of Ebola Vaccines intended for emergency use, WHO/HQ Geneva, Switzerland, 18-19 March 2015
  • WHO Informal Consultation on Stability Evaluation of Vaccines for use in a Controlled Temperature Chain, WHO/HQ Geneva, Switzerland, 24–26 March 2015
  • WHO Informal Consultation on Amendment for Similar Biotherapeutic products of monoclonal antibodies, WCC, Geneva, Switzerland, 27–28 April 2015
  • WHO Informal Consultation on Regulatory risk assessment for biotherapeutic products, WCC, Geneva, Switzerland, 29–30 April 2015

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971